natgillin/translations-raw huggingface dataset:
BTV2 antigen .................................................................................................................6.8–9.5 CCID50*
BTV2 antigen ...............................................................................................................6,8 – 9,5 CCID50
BTV4 antigen .................................................................................................................7.1–8.5 CCID50*
BTV4 antigen ...............................................................................................................7,1 – 8,5 CCID50
BTVPUR AlSap 1 suspension for injection for sheep and cattle
BTVPUR AlSap 1 suspenzija za injekciju za ovce i goveda
BTVPUR AlSap 1 suspension for injection for sheep and cattle
BTVPUR AlSap 1 suspenzija za injekciju za ovce i goveda.
BTVPUR AlSap 1 suspension for injection for sheep and cattle.
BTVPUR AlSap 1 suspenzija za injekciju za ovce i goveda.
BTVPUR AlSap 2-4 suspension for injection for sheep
BTVPUR AlSap 2-4 suspenzija za injekciju za ovce
BTVPUR AlSap 2-4 suspension for injection for sheep
BTVPUR AlSap 2-4 suspenzija za injekciju za ovce.
BTVPUR AlSap 2-4suspension for injection for sheep
BTVPUR AlSap 2-4 suspenzija za injekciju za ovce.
BTVPUR AlSap 8 suspension for injection
BTVPUR AlSap 8 suspenzija za injekciju
BTVPUR AlSap 8 suspension for injection
BTVPUR AlSap 8 suspenzija za injekciju.
BTVPUR AlSap 8, suspension for injection
BTVPUR AlSap 8, suspenzija za injekciju.
BTVPUR contains bluetongue virus of one or two types selected from serotypes 1, 4 and 8.
BTVPUR sadržava virus bolesti plavog jezika jednog ili dvaju serotipova odabranih među serotipovima 1, 4 i 8.
BTVPUR injection for sheep and cattle
BTVPUR injekcija za ovce i goveda.
BTVPUR is a vaccine used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
BTVPUR je cjepivo koje se primjenjuje u ovaca i goveda radi zaštite od bolesti plavog jezika, infekcije uzrokovane virusom bolesti plavog jezika koji prenose mušice.
BTVPUR is developed from AlSap 1-8 originally authorised under ‘exceptional circumstances’ on 17 December 2010 because limited information was available at the time of approval.
VMP BTVPUR razvijen je iz lijeka AlSap 1 – 8, koji je izvorno odobren u „iznimnim okolnostima” 17. prosinca 2010. jer su u trenutku izdavanja odobrenja bile dostupne ograničene informacije o lijeku.
BTVPUR suspension for injection for sheep and cattle
BTVPUR suspenzija za injekciju za ovce i goveda.
BTVPUR suspension for injection for sheep and cattle.
BTVPUR suspenzija za injekciju za ovce i goveda.
Buccal disorders
Bukalni poremećaji
BUCCOLAM 10 mg oromucosal solution
BUCCOLAM 10 mg otopina za usnu sluznicu
BUCCOLAM 10 mg oromucosal solution For children aged 10 years to less than 18 years
BUCCOLAM 10 mg otopina za usnu sluznicu Za djecu u dobi od 10 godina do manje od 18 godina
BUCCOLAM 2.5 mg oromucosal solution
BUCCOLAM 2,5 mg otopina za usnu sluznicu
BUCCOLAM 2.5 mg oromucosal solution For children aged 3 months to less than 1 year
BUCCOLAM 2,5 mg otopina za usnu sluznicu Za djecu u dobi od 3 mjeseca do manje od 1 godine
BUCCOLAM 5 mg oromucosal solution
BUCCOLAM 5 mg otopina za usnu sluznicu
BUCCOLAM 5 mg oromucosal solution For children aged 1 year to less than 5 years
BUCCOLAM 5 mg otopina za usnu sluznicu Za djecu u dobi od 1 godine do manje od 5 godina
BUCCOLAM 5 mg oromucosal solution midazolam
BUCCOLAM 5 mg otopina za usnu sluznicu midazolam
BUCCOLAM 7.5 mg oromucosal solution
BUCCOLAM 7,5 mg otopina za usnu sluznicu
BUCCOLAM 7.5 mg oromucosal solution For children aged 5 years to less than 10 years
BUCCOLAM 7,5 mg otopina za usnu sluznicu Za djecu u dobi od 5 godina do manje od 10 godina
BUCCOLAM contains a medicine called midazolam.
BUCCOLAM sadrži lijek zvan midazolam.
BUCCOLAM is available in cartons containing 4 pre-filled syringes.
BUCCOLAM se isporučuje u kutijama koje sadrže 4 napunjene štrcaljke
Bucharest 032266 Romania
Bukurešt 032266 Rumunjska
Buckinghamshire HP7 9NA United Kingdom
Little Chalfont Buckinghamshire HP7 9NA Ujedinjeno Kraljevstvo
Buckinghamshire, MK7 7AJ UNITED KINGDOM
Buckinghamshire, MK7 7AJ Ujedinjeno Kraljevstvo
Bucks HP7 9NA United Kingdom
Bucks HP7 9NA Ujedinjeno Kraljevstvo
Budapest H-1047
Budimpešta H-1047
Budd–Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins)
Budd–Chiarijev sindrom (klinički simptomi uzrokovani začepljenjem jetrenih vena)
budesonide / formoterol fumarate dihydrate
budezonid / formoterolfumarat dihidrat
budesonide / formoterol fumarate dihydrate
budezonid/ formoterolfumarat dihidrat
Budesonide belongs to a group of medicines called ‘corticosteroids’ also known as ‘steroids’.
Budezonid pripada skupini lijekova pod nazivom „kortikosteroidi” poznati i kao 'steroidi'.
Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budezonid ima visok sistemski klirens (oko 1,2 l/min) a poluvrijeme eliminacije iz plazme nakon i.v. doziranja prosječno iznosi 4 sata.
Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
Budezonid ima visok sistemski klirens (oko 1,2 l/min), a poluvrijeme eliminacije iz plazme nakon i.v. doziranja prosječno iznosi 4 sata.
budesonide, inhaled/nasal fluticasone, dexamethasone if taken by mouth or through injection
budezonid, inhalacijski flutikazon ili flutikazon za primjenu u nos, deksametazon ako se uzima kroz usta ili prima injekcijom
budesonide/ formoterol fumarate dihydrate
budezonid/ formoterolfumarat dihidrat
budesonide/formoterol fumarate dihydrate
budezonid/ formoterolfumarat dihidrat
budesonide/formoterol fumarate dihydrate
budezonid/ formoterolfumarat dihidrat.
budesonide/formoterol fumarate dihydrate
budezonid/formoterolfumarat dihidrat
Budesonide/Formoterol Furmarate Dihydrate
Budezonid/formoterol fumarat dihidrat 160/4,5
Budesonide/Formoterol Furmarate Dihydrate 160/4.5 µg bd + as needed
Budezonid/formoterol fumarat dihidrat 160/4,5 µg dvaput dnevno + po potrebi
Budesonide/Formoterol Furmarate Dihydrate 320/9 µg bd + terbutaline 0.4 mg as needed
Budezonid/formoterol fumarat dihidrat 320/9 µg dvaput dnevno + terbutalin 0,4 mg po potrebi
Budesonide/formoterol maintenance and reliever therapy
Terapija održavanja i terapija ublažavanja akutnih simptoma astme budezonidom/formoterolom
Budesonide/Formoterol Teva
Budezonid/Formoterol Teva
Budesonide/Formoterol Teva 160 mcg/4.5 mcg
Budezonid/Formoterol Teva 160 mcg/4,5 mcg
Budesonide/Formoterol Teva 160 mcg/4.5 mcg inhalation powder
Budezonid/Formoterol Teva 160 μg/4,5 μg prašak inhalata
Budesonide/Formoterol Teva 160 micrograms / 4.5 micrograms inhalation powder
Budezonid/Formoterol Teva 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva 160 micrograms /4.5 micrograms inhalation powder
Budezonid/Formoterol Teva 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva 160 micrograms/4.5 micrograms, inhalation powder
Budezonid/Formoterol Teva 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva 320 mcg/9 mcg inhalation powder
Budezonid/Formoterol Teva 320 µg/9 µg prašak inhalata.
Budesonide/Formoterol Teva 320 micrograms/9 micrograms should be used as maintenance therapy only.
Budezonid/Formoterol Teva od 320 mikrograma/9 mikrograma treba koristiti samo kao terapiju održavanja.
Budesonide/Formoterol Teva 320 micrograms/9 micrograms, inhalation powder
Budezonid/Formoterol Teva 320 mikrograma/9 mikrograma prašak inhalata
Budesonide/Formoterol Teva budesonide / formoterol
Budesonide/Formoterol Teva budezonid / formoterol
Budesonide/Formoterol Teva can also be used to treat the symptoms of severe COPD in adults.
Budezonid/Formoterol Teva također se može koristiti za liječenje simptoma teškog KOPB-a u odraslih.
Budesonide/Formoterol Teva contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations.
Budezonid/Formoterol Teva sadrži formoterol i budezonid koji imaju različite mehanizme djelovanja i pokazuju aditivne učinke u smislu smanjenja egzacerbacija astme.
Budesonide/Formoterol Teva contains lactose
Budezonid/Formoterol Teva sadrži laktozu
Budesonide/Formoterol Teva contains two different active substances: budesonide and formoterol fumarate dihydrate.
Budezonid/Formoterol Teva sadrži dvije različite djelatne tvari: budezonid i formoterolfumarat dihidrat.
Budesonide/Formoterol Teva has no or negligible influence on the ability to drive and use machines.
Budezonid/Formoterol Teva ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Budesonide/Formoterol Teva is a medicine that contains the active substances budesonide and formoterol.
Budesonide/Formoterol Teva je lijek koji sadrži djelatne tvari budezonid i formoterol.
Budesonide/Formoterol Teva is a ‘hybrid medicine’.
Budesonide/Formoterol Teva je „hibridni lijek”.
Budesonide/Formoterol Teva is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare–ups) of the disease in the past despite regular treatment.
Budesonide/Formoterol Teva također se koristi za ublažavanje simptoma ozbiljne kronične opstruktivne pulmonalne bolesti (KOPB-a) u odraslih osoba koje su imale eksacerbacije (pogoršanja) bolesti u prošlosti usprkos redovitom liječenju.
Budesonide/Formoterol Teva is an inhalation powder.
Budezonid/Formoterol Teva je prašak inhalata.
Budesonide/Formoterol Teva is indicated for use in adults 18 years of age and older only.
Primjena lijeka Budezonid/Formoterol Teva indicirana je samo za odrasle u dobi od 18 i više godina.
Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.
Budezonid/Formoterol Teva indiciran je samo u odraslih u dobi od 18 godina i starijih.
Budesonide/Formoterol Teva is indicated in adults 18 years of age and older only.
Budezonid/Formoterol Teva indiciran je samo u odraslih u dobi od 18 godina i više.
Budesonide/Formoterol Teva is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
Budezonid/Formoterol Teva je indiciran u redovitom liječenju astme kad je primjereno kombinirano liječenje (inhalacijskim kortikosteroidom i dugodjelujućim agonistima ß2-adrenergičkih receptora):
Budesonide/Formoterol Teva is not an appropriate treatment for the adult patient with only mild asthma who is not adequately controlled with an inhaled corticosteroid and “as needed” inhaled short-acting β2 adrenoreceptor agonists.
Budezonid/Formoterol Teva nije odgovarajuće liječenje za odraslog bolesnika koji ima samo blagi oblik astme i koji nije zadovoljavajuće kontroliran inhalacijskim kortikosteroidom i „prema potrebi“ inhalacijskim ß2 adrenoreceptorskim agonistima kratkog djelovanja.
Budesonide/Formoterol Teva is not an appropriate treatment for the adult patient with only mild asthma who is not adequately controlled with an inhaled corticosteroid and “as needed” inhaled short-acting β2 adrenoreceptor agonists.
Budezonid/Formoterol Teva nije odgovarajuće liječenje za odraslog bolesnika koji ima samo blagi oblik astme i koji nije zadovoljavajuće kontroliran inhalacijskim kortikosteroidom i ″prema potrebi″ inhalacijskim ß2-adrenoreceptorskim agonistima kratkog djelovanja.
Budesonide/Formoterol Teva is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Budezonid/Formoterol Teva NIJE indiciran za primjenu u djece s navršenih 12 godina i mlađu niti za adolescente u dobi od 13 do 17 godina.
Budesonide/Formoterol Teva is not indicated in children and adolescents under the age of 18 years (see section 4.2).
Budezonid/Formoterol Teva nije indiciran u djece i adolescenata u dobi manjoj od 18 godina starosti (vidjeti dio 4.2).
Budesonide/Formoterol Teva is not intended for the initial management of asthma.
Budezonid/Formoterol Teva nije namijenjen za početno zbrinjavanje astme.
Budesonide/Formoterol Teva is not likely to affect your ability to drive or to use tools or machines.
Budezonid/Formoterol Teva vjerojatno neće utjecati na Vašu sposobnost upravljanja vozilima, alatima ili strojevima.
Budesonide/Formoterol Teva is taken as regular maintenance treatment with a separate rapid-acting bronchodilator reliever inhaler.
Budezonid/Formoterol Teva uzima se kao redovita terapija održavanja s posebnim inhalatorom koji sadrži brzodjelujući bronhodilatator za hitno simptomatsko liječenje.
Budesonide/Formoterol Teva Pharma B.V.
Budezonid/Formoterol Teva Pharma B.V.
Budesonide/Formoterol Teva Pharma B.V. 160 mcg/4.5 mcg
Budezonid/Formoterol Teva Pharma B.V. 160 mcg/4,5 mcg
Budesonide/Formoterol Teva Pharma B.V. 160 mcg/4.5 mcg inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 160 μg/4,5 μg prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms / 4.5 micrograms inhalation powder.
Budezonid/Formoterol Teva Pharma B.V. 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms /4.5 micrograms inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 160 micrograms/4.5 micrograms, inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 160 mikrograma/4,5 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 320 micrograms/9 micrograms inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 320 mikrograma/9 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. 320 micrograms/9 micrograms inhalation powder.
Budezonid/Formoterol Teva Pharma B.V. 320 mikrograma/9 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V. contains lactose
Budezonid/Formoterol Teva Pharma B.V. sadrži laktozu
Budesonide/Formoterol Teva Pharma B.V. contains two different active substances: budesonide and formoterol fumarate dihydrate.
Budezonid/Formoterol Teva Pharma B.V. sadrži dvije različite djelatne tvari: budezonid i formoterolfumarat dihidrat.
Budesonide/Formoterol Teva Pharma B.V. is a ‘hybrid medicine’.
Budesonide/Formoterol Teva Pharma B.V. je „hibridni lijek”.
Budesonide/Formoterol Teva Pharma B.V. is an inhalation powder.
Budezonid/Formoterol Teva Pharma B.V. je prašak inhalata.
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.
Budezonid/Formoterol Teva Pharma B.V. indiciran je samo u odraslih u dobi od 18 godina i više.
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a
Budezonid/Formoterol Teva Pharma B.V. je indiciran u redovitom liječenju astme kad je primjereno
Budesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
Budezonid/Formoterol Teva Pharma B.V. je indiciran u redovitom liječenju astme kad je primjereno kombinirano liječenje (inhalacijskim kortikosteroidom i dugodjelujućim agonistima ß2-adrenergičkih receptora):
Budesonide/Formoterol Teva Pharma B.V. is NOT indicated for use in children 12 years of age and younger or adolescents 13 to 17 years of age.
Budezonid/Formoterol Teva Pharma B.V. NIJE indiciran za primjenu u djece s navršenih 12 godina i mlađu niti za adolescente u dobi od 13 do 17 godina.
Budesonide/Formoterol Teva Pharma B.V. is NOT indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Budezonid/Formoterol Teva Pharma B.V. NIJE indiciran za primjenu u djece s navršenih 12 godina i mlađu niti za adolescente u dobi od 13 do 17 godina.
Budesonide/Formoterol Teva Pharma B.V. is not indicated for use in children, 12 years of age and younger or adolescents, 13 to 17 years of age.
Budezonid/Formoterol Teva Pharma B.V. nije indiciran za primjenu u djece, u dobi od 12 godina i mlađe, niti za adolescente u dobi od 13 do 17 godina.
Budesonide/Formoterol Teva Pharma B.V. is taken as regular maintenance treatment with a separate rapid- acting bronchodilator reliever inhaler.
Budezonid/Formoterol Teva Pharma B.V. uzima se kao redovita terapija održavanja s posebnim inhalatorom koji sadrži brzodjelujući bronhodilatator za hitno simptomatsko liječenje.
Budesonide/Formoterol Teva Pharma B.V. should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
Budezonid/Formoterol Teva Pharma B.V. se mora trenutno prekinuti, bolesnika se mora procijeniti , te po potrebi, treba mu uvesti drugu terapiju (vidjeti dio 4.4).
Budesonide/Formoterol Teva Pharma B.V.320 mcg/9 mcg
Budezonid/Formoterol Teva Pharma B.V. 320 mcg/9 mcg
Budesonide/Formoterol Teva Pharma B.V.320 mcg/9 mcg inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 320 µg/9 µg prašak inhalata.
Budesonide/Formoterol Teva Pharma B.V.320 micrograms/9 micrograms inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 320 mikrograma/9 mikrograma prašak inhalata
Budesonide/Formoterol Teva Pharma B.V.320 micrograms/9 micrograms, inhalation powder
Budezonid/Formoterol Teva Pharma B.V. 320 mikrograma/9 mikrograma prašak inhalata
Budesonide/Formoterol Teva should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
Budezonid/Formoterol Teva se mora trenutno prekinuti, bolesnika se mora procijeniti , te po potrebi, treba mu uvesti drugu terapiju (vidjeti dio 4.4).
Budesonide/Formoterol Teva should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
Budezonid/Formoterol Teva se mora trenutno prekinuti, bolesnika se mora procijeniti, te po potrebi, treba mu uvesti drugu terapiju (vidjeti dio 4.4).
Budesonide/Formoterol Teva should be used correctly in order to achieve effective treatment.
Budezonid/Formoterol Teva se mora koristiti pravilno kako bi se postiglo učinkovito liječenje.
Buffered isotonic solution to 1 ml.
Izotonična puferska otopina do 1 ml
Buffered isotonic solution to 1 ml.
Izotonična puferska otopina do:
Buffered isotonic solution to 1 ml.
Izotonična puferska otopina do: 1 ml
Build up of fluid around the lungs leading to chest pain and difficulty in breathing (pleural effusion); wheezing
Nakupljanje tekućine oko pluća, što dovodi do bolova u prsnom košu i otežanoga disanja (pleuralni izljev), zviždanje u prsima.
Build-up of thick and sticky secretions in the lungs causes inflammation and long- term infection.
Nakupljanje debelih i ljepljivih izlučevina u plućima uzrokuje upalu i dugotrajnu infekciju.
Build-up of thick and sticky secretions in the lungs causes inflammation and long-term infection.
Nakupljanje gustog i ljepljivog sekreta u plućima uzrokuje upalu i dugotrajnu infekciju.
Bulging belly button
Ispupčenje pupka
Bulging eyes
izbuljene oči
Bulky disease
Prošireni tumori
Bulky disease
velika tumorska masa
Bulky disease:
Prošireni tumori:
Bullous conditions (blistering skin diseases)-including Stevens-Johnson syndrome and Toxic epidermal necrolysis
Bulozna stanja (bolesti kože kod kojih se stvaraju mjehurići na koži) – uključujući Stevens- Johnsonov sindrom i toksičnu epidermalnu nekrolizu
Bullous conditions (blistering skin diseases)-including Stevens-Johnson syndrome and Toxic epidermal necrolysis
Bulozna stanja (bolesti kože kod kojih se stvaraju mjehurići na koži) – uključujući Stevens-Johnsonov sindrom i toksičnu epidermalnu nekrolizu
Bullous conditions including Toxic epidermal necrolysis, Stevens Johnson syndrome and erythema multiforme
Bulozna stanja uključujući toksičnu epidermalnu nekrolizu, Stevens- Johnsonov sindrom i eritema multiforme
Bullous dermatitis
bulozni dermatitis
Bullous dermatitis
Poreme ćaji mišićno
Bullous eruption, dermatitis, erythematous rash, nail disorder, scaly skin
bulozna erupcija, dermatitis, eritematozni osip, poremećaj noktiju, ljuskava koža
Bullous eruptions
bulozne erupcije
Bullous or exfoliative skin lesions
Bulozne ili eksfolijativne kožne lezije
bullous pemphigoid*
bulozni pemfigoid
Bullous photosensitivity
povećana osjetljivost na svjetlost popraćena mjehurićima
Bullous†
dermatitis
bumpy rash (papular rash)
osip sa sitnim kvržicama (papularni osip)
bumpy rash blood infection
uzdignuti osip infekcija krvi
bumpy rash blood infection.
uzdignuti osip infekcija krvi
Bun increase
transaminaze
Bundle branch block
blok grane
Bundle branch block
blok grane snopa
Bundle pack of 3 single packs.
Višestruko pakiranje od 3 pojedinačna pakiranja.
buprenorphin
Teriflunomi
Buprenorphine
Buprenorfin
Buprenorphine 16 q24h 100 q12h ↑ 57% ↑ 77%
Buprenorfin 16 svakih 24h 100 svakih 12h ↑ 57% ↑ 77
buprenorphine AUC ↑ 19%
buprenorfin AUC ↑ 19
Buprenorphine AUC ↑67% Buprenorphine Cmax ↑37% Buprenorphine Cmin ↑69%
Buprenorfin AUC ↑67% Buprenorfin Cmax ↑37% Buprenorfin Cmin ↑69
Buprenorphine AUC: ↑35% Buprenorphine Cmax: ↑66% Buprenorphine Cmin: ↑12%
Buprenorfin AUC: ↑35% Buprenorfin Cmax: ↑66% Buprenorfin Cmin: ↑12
buprenorphine Cmax ↑ 18%
buprenorfin Cmax ↑ 18
buprenorphine Cmin ↑ 31%
buprenorfin Cmin ↑ 31
Buprenorphine ↔
Buprenorfin ↔
Buprenorphine ↔
Opioidni analgetici
Buprenorphine, 16 mg QD
Buprenorfin, 16 mg QD
buprenorphine, a medicine used for the treatment of chronic pain;
buprenorfin, koji se koristi za liječenje kronične boli;
buprenorphine.
buprenorfinom.
buprenorphine/naloxone
prilagođavati dozu
Buprenorphine/Naloxone
tipranavira.
Buprenorphine/Naloxone (16/4 mg
Buprenorfin/nalokson (16/4 mg do
Buprenorphine/Naloxone (16/4 to
Buprenorfin/nalokson (16/4 do
Buprenorphine/naloxone (medicines to treat opiate dependence)
buprenorfin/nalokson (lijekovi za liječenje ovisnosti o opijatima)
buprenorphine/naloxone (medicines used to treat severe pain)
buprenorfin/nalokson (lijekovi koji se primjenjuju u liječenje teške boli)
buprenorphine/naloxone (medicines used to treat severe pain)
buprenorfin/nalokson (lijekovi koji se primjenjuju za liječenje teške boli)
Buprenorphine/naloxone 8/2 mg–16/4 mg once daily
Buprenorfin/nalokson
Buprenorphine/naloxone has minor to moderate influence on the ability to drive and use machines when administered to opioid dependent patients.
Buprenorfin/nalokson malo do umjereno utječe na sposobnost upravljanja vozilima i rad na strojevima kad se primjenjuje u bolesnika ovisnih o opioidima.
Buprenorphine/naloxone is contraindicated in patients with severe hepatic impairment. (see section 4.3 and 5.2).
Buprenorfin/nalokson kontraindiciran je u bolesnika s teškim oštećenjem jetre (vidjeti dijelove 4.3 i 5.2.).
Buprenorphine/naloxone may cause severe, possibly fatal, respiratory depression in children and non- dependent persons in case of accidental or deliberate ingestion.
Buprenorfin/nalokson u djece i osoba koje nisu ovisne može, u slučaju nehotičnog ili hotimičnog gutanja, uzrokovati tešku, potencijalno po život opasnu depresiju disanja.
Buprenorphine/Naloxone*
Buprenorfin/nalokson
Buprenorphine/naloxone/Efavirenz
buprenorfin/nalokson/efavirenz
Buprenorphine/naloxone/Efavirenz
buprenorfin/nalokson/emtricitabin
Buprenorphine/naloxone/Efavirenz
metadon/emtricitabin
Buprenorphine/naloxone/Emtricitabine
buprenorfin/nalokson/emtricitabin
Buprenorphine/naloxone/Tenofovir disoproxil fumarate
buprenorfin/nalokson/tenofovirdizoproksil fumarat
Buprenorphine:
Buprenorfin:
Buprenorphine: AUC: ↑ 1.5-fold Cmax: ↑1.7-fold
AUC: ↑ 1,5 puta Cmax: ↑ 1,7 puta
Buprenorphine: AUC: ↓ 50%
buprenorfin/nalokson/efavirenz
Buprenorphine: AUC: ↓ 50%
Buprenorfin: AUC: ↓ 50
Buprenorphine: ↔
Buprenorfin: ↔
Bupropion
12h
bupropion (a medicine to treat depression also used to wean from smoking). fluoxetine, paroxetine and other medicines to treat depression called SSRI/SNRIs, tricyclics.
bupropion (lijek za liječenje depresije koji se također koristi za odvikavanje od pušenja). fluoksetin, paroksetin i drugi lijekovi za liječenje depresije koji se zovu SSRI/SNRI-i, triciklici gospinu travu (Hypericum perforatum) (lijek za liječenje depresije).